| Company/Division name | Bristol Myers Squibb |
| Parent company | Bristol Myers Squibb |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2023 |
| City reshored to: | Devens |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell therapy manufacturing |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D) |
